# Rubicon Research share price today (Rubicon Research Ltd, NSE: RUBICON) > Rubicon Research share price today: ₹1,658.30 at the NSE close on 18 November 2026, up 144.6% in a year. Rubicon Research (NSE: RUBICON) is worth ₹27,454 crore, trades at a P/E of 84.3 and has closed between ₹615.20 and ₹1,860.60 over the past 52 weeks. > Rubicon Research Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. RUBICON · Pharma - Formulators · data as of 18 November 2026. Page: https://www.sectoralpha.in/stocks/rubicon-research-ltd Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms ## Key numbers - Price: ₹1,658.30 (+144.6% in a year) - P/E: 84.3× (higher than 60% of the last 1 year) - Revenue (Sep 2026): ₹576 Cr (+39.8% on a year ago) - Profit (Sep 2026): ₹90.0 Cr (+66.7% on a year ago) - Operating margin: 25.0% (+2.2 points on a year ago) - ROCE: 28%, FY26 - ROIC: 23.7%, against a 12.0% cost of capital: +11.7 points - Profit that came in as cash: 82%, last 3 years The main question: the share price moved +144.6% in a year while yearly earnings per share moved +71.4%. The difference came from the market paying a higher multiple. ## What is the Rubicon Research share price today? Rubicon Research Ltd's share price was ₹1,658.30 at the close on 18 November 2026. It has been rising for 48 weeks. That is 24.5% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹615 and ₹1,861, and at that close it sat 84% of the way up from that low. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 2 weeks running. Over the last 1 year the share price moved +168% while the NIFTY 500 moved +1%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 8 November 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Rubicon Research this quarter? Three changes stood out: promoters cut their stake for 3 quarters in a row, best operating margin in 9 quarters and revenue up on a year earlier for 5 quarters in a row (every quarter we can compare). 1. Promoters cut their stake for 3 quarters in a row From 60% to 51.3% of the company by the September 2026 quarter. 2. Best operating margin in 9 quarters Operating margin was 25% in the September 2026 quarter, against 23% a year earlier. Why: The margin improved because more sales came from specialty products, it won more business, and it had mostly finished exiting low margin products. Next results: check whether the full year lands at the new 24% plus level. From the earnings call on 5 Nov 2026. 3. Revenue up on a year earlier for 5 quarters in a row (every quarter we can compare) In the September 2026 quarter revenue was ₹576 crore, +39.8% on a year earlier. Why: Revenue rose because more product lines brought in money and specialty products held their prices. Next results: check whether the delayed launches turn into shipments next quarter. From the earnings call on 5 Nov 2026. ## What are Rubicon Research's latest quarterly results? For July to September 2026 (the quarter ended 30 September 2026), Rubicon Research reported revenue of ₹576 crore, up 39.8% from ₹412 crore a year earlier, and a profit of ₹90.0 crore, up 66.7% from ₹54.0 crore. ### Rubicon Research results: July to September 2026 against a year earlier | Measure | July to September 2026 | July to September 2025 | Change | | --- | --- | --- | --- | | Revenue | ₹576 crore | ₹412 crore | +39.8% | | Profit | ₹90.0 crore | ₹54.0 crore | +66.7% | | Earnings per share | ₹5.47 | ₹3.49 | +56.7% | | Operating margin | 25.0% | 22.8% | +2.2 points | The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Rubicon Research's management discussed these results on a call held on 5 November 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.) ## What is the Rubicon Research share price history? Rubicon Research closed at ₹1,658.30 on 18 November 2026, up 144.6% from ₹677.90 a year earlier (21 November 2025). Its highest weekly close since October 2025 was ₹1,835.40 on 11 September 2026. ### Rubicon Research share price: then and now | When | Close | Change to 18 Nov 2026 | | --- | --- | --- | | 1 week ago · 11 Nov 2026 | ₹1,723.30 | −3.8% | | 1 month ago · 19 Oct 2026 | ₹1,486.70 | +11.5% | | 6 months ago · 15 May 2026 | ₹960.95 | +72.6% | | 1 year ago · 21 Nov 2025 | ₹677.90 | +144.6% | | Earliest weekly close in our records · 17 Oct 2025 | ₹618.80 | +168.0% | | Highest weekly close since October 2025 · 11 Sep 2026 | ₹1,835.40 | −9.6% | | Lowest weekly close since October 2025 · 24 Oct 2025 | ₹577.25 | +187.3% | | 52-week high (weekly close) · 8 Sep 2026 | ₹1,860.60 | −10.9% | | 52-week low (weekly close) · 8 Dec 2025 | ₹615.20 | +169.6% | Weekly closing prices. Each change is the move from that price to the 18 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (66 weekly closes from 17 October 2025 to 18 November 2026.) ## What is the latest news on Rubicon Research? 18 Nov 2026: Rubicon Research closed at ₹1,658.30, down 3.8% on the week and up 11.5% on the month. 5 Nov 2026: Rubicon Research held its results call for July to September 2026. Management guided: FY27 operating margin at 24% plus. ### Earlier - Results for July to September 2026: Revenue up 39.8% and profit up 66.7% on a year earlier. - 7 Aug 2026: ex-date for a dividend of ₹1.50 a share. ## What dividend does Rubicon Research pay? Rubicon Research paid ₹1.50 a share in regular dividends in the 12 months to 18 November 2026 (1 payment), a yield of 0.09% at the ₹1,658.30 close on 18 November 2026. The last was a dividend of ₹1.50 a share, ex-date 7 August 2026. ### Rubicon Research dividends since 1 April 2021 | Ex-date | Dividend per share | Type | | --- | --- | --- | | 7 Aug 2026 | ₹1.50 | Dividend | Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here. 0 of 5 Of the last 5 financial years, years with an NSE dividend record Yes. Rubicon Research Ltd paid out 10% of its profit as dividends in FY26, and it paid a dividend in 3 of its last 7 reported years. One of those years shows a negative figure because profit itself was negative. (From the NSE corporate-actions record, read 18 November 2026.) ## What did Rubicon Research management say on the latest results call? On the call for July to September 2026, held on 5 November 2026, Rubicon Research's management guided: FY27 operating margin at 24% plus. > “We are happy to report that we are now guiding to 24% plus for the full year.” > Parag Sancheti, on the call for July to September 2026 ### What management guided - Cumulative R&D ₹500 crore over FY26 through April to June 2027 with ₹313 crore spent in 6 quarters on track. - Pithampur revenue contribution from FY28 onward. - Sequential dollar growth to continue in coming quarters on strong visibility. - Arinna to return to growth then beat IPM growth before margin focus. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/58246/Conference Call/CC-Nov26.pdf). (From the call for July to September 2026, 5 November 2026.) ## What to watch in Rubicon Research's next results? When Rubicon Research reports October to December 2026, these are the 2 checks that show whether the story is still on course. First: Delayed launches from revised export licensing converting to shipments next quarter - per shift to post-approval submissions. Management raised each of these on the latest results call. - Delayed launches from revised export licensing converting to shipments next quarter - per shift to post-approval submissions. - EIR outcomes for October manufacturing inspections and July response closing cleanly - per timely-close confidence. ## Which stock lists is Rubicon Research on? Rubicon Research is on 2 of our India lists: Small & mid cap stocks and Pharma stocks. - [Small & mid cap stocks Size rank in India: 301](https://www.sectoralpha.in/small-cap-stocks-india) - [Pharma stocks Market value: ₹27,875 crore](https://www.sectoralpha.in/sectors/pharma-stocks-india) ## Is Rubicon Research profitable? Rubicon Research Ltd earned ₹90.0 Cr of net profit in the Sep 2026 quarter, +66.7% on the same quarter a year earlier. That is the 6th quarter in a row of profit growth. Full-year FY26 profit was ₹247 Cr. Over 6 years profit has grown 30.9% a year on average. The same quarter a year earlier earned ₹54.0 Cr. The Sep 2026 quarter's profit is 15.6% of that quarter's revenue. For the full year, FY26 profit was ₹247 Cr (+84.3% on the year before). Why profit moved: revenue changed +39.8% on a year earlier and the margin moved +2.2 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed +92.6% and revenue +46.8%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. ## How much revenue does Rubicon Research make, and is it growing? Rubicon Research Ltd reported ₹576 Cr of revenue in the Sep 2026 quarter, +39.8% on the same quarter a year earlier. That is the 6th quarter in a row with growth on the year before. Over 6 years it has grown 37.2% a year on average. The last full year, FY26, came in at ₹1,754 Cr. The last four reported quarters add to ₹2,100 Cr. FY26 revenue was ₹1,754 Cr, +36.6% on the year before. Recent pace: the last four quarters grew +46.8% on average, against 37.2% a year over the longer run, so this year is growing faster than its own long-run rate. ## How much of every ₹100 of sales does Rubicon Research keep? Rubicon Research Ltd's operating margin was 25.0% in the Sep 2026 quarter, 2.2 percentage points higher than the same quarter a year ago. Across 7 years it has been between −12.4% and 30.8%. The latest quarter is within that range. Why the margin moved: operating margin changed +2.1 percentage points on the year while gross margin changed −0.7 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Rubicon Research's profit turning into cash? Over the last 3 years, 82% of Rubicon Research Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹205 Cr of operating cash against ₹247 Cr of profit. After ₹229 Cr of spending on assets, free cash was −₹24.0 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 82% of profit came in as cash: the cash cycle got 24 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner. What to look at next: the bigger use of cash is spending on new assets, at 2.9× depreciation over three years. The next section checks what that spending is building. ## Where does Rubicon Research's cash go? Rubicon Research Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 371 days in FY26, down from 395 days in FY21. It spent ₹355 Cr on assets over the last 3 years. Customers take 106 days to pay, and stock sits for 550 days on average. At FY26 sales of ₹1,754 Cr, each day of that cycle ties up about ₹4.8 Cr, so roughly ₹1,783 Cr is tied up in the business at any time. FY26: customers took 106 days to pay and stock sat for 550 days, about 18.1 months of sales sitting as stock, for a full cycle of 371 days, shorter than FY21's 395. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 550 days. Customers pay about 106 days after that. Suppliers are paid at 285 days. Together that makes the 371-day cycle. Spending on assets: ₹355 Cr over the last 3 years, against ₹121 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹41.0 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Rubicon Research's P/E ratio, and how does it compare with its own history? Rubicon Research Ltd's P/E is 84.3×, in the middle of its own history: higher than 60% of past readings. Its usual P/E (the middle reading) is 76.9×, over 1 year of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +71.4% while the price moved +144.6%. The price did better than earnings, which pushed the multiple up within its own range. In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Rubicon Research business getting better or worse? Rubicon Research Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 7 quarters of 1 measure, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Rubicon Research earn on its capital? Rubicon Research Ltd earned a ROCE of 28% in FY26. That is up from a low of −12% in FY22. Its return on capital used (ROIC) is 11.7 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 14.1% net margin and 0.75× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 14.1% net margin × 0.75× asset turnover × 1.81× leverage (assets divided by equity) ≈ 19.1% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 23.7% − 12.0% = +11.7 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value. The 23.7% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 25.6%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Rubicon Research have too much debt? Rubicon Research Ltd has total debt of ₹501 Cr against shareholder equity of ₹1,417 Cr as of Sep 2026, so its debt is 0.35× its equity. Year by year, that ratio went from 0.80 in FY25 to 0.24 in FY26. Keep that borrowing in mind when reading the returns on this page. ## What is the Rubicon Research shareholding pattern? No group of Rubicon Research Ltd's owners changed its stake by a full percentage point over the last 4 quarters. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. ## How far is Rubicon Research from balance-sheet trouble? For Rubicon Research Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Rubicon Research rank in its industry? 67.4 out of 100, rank 4 of 44 in Pharma - Formulators, with 87% of the evidence available. Rubicon Research Ltd scores 67.4 out of 100 against the 44 companies it is compared with in Pharma - Formulators, ranking 4. Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. The four parts add up to the total exactly: 24 + 18.8 + 8.1 + 16.5 = 67.4. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Rubicon Research compared with? Rubicon Research ranks 4 of 44 Pharma - Formulators companies on the 4-Factor Sector Score, with 67.4 out of 100. 1. [Marksans Pharma Ltd](https://www.sectoralpha.in/stocks/marksans-pharma-ltd) MARKSANS · losing its lead · Most evidence points up · 78% evidence 75.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.5/35 · Revenue 24.2% · Profit 60.3% · Operating margin change 3 points · 100% evidence Capital efficiency 18.0/25 · ROCE 18.8% (year to Mar 2026) · Operating margin 22.8% · 100% evidence Valuation 15.4/20 · P/E 23.8× · PEG 0.92 · 65% evidence Relative strength 11.9/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) 31.3% · 1 year 53.6% · 25% evidence · 11 of 12 weeks ahead Exact sum: 30.5 + 18 + 15.4 + 11.9 = 75.8 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Emcure Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/emcure-pharmaceuticals-ltd) EMCURE · leader · Most evidence points up · 75% evidence 72.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.1/35 · Revenue 21.1% · Profit 33.3% · Operating margin change 0 points · 95% evidence Capital efficiency 18.0/25 · ROCE 24% (year to Mar 2026) · Operating margin 20.9% · 76% evidence Valuation 10.0/20 · P/E 40.5× · PEG n/a · 15% evidence Relative strength 18.7/20 · Strength vs its industry (price vs its 52-week average, weekly) 17.5% · Strength vs NIFTY 500 (same reading) 33.7% · 1 year 72.4% · 100% evidence · 10 of 12 weeks ahead Exact sum: 26.1 + 18 + 10 + 18.7 = 72.8 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Kwality Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/kwality-pharmaceuticals-ltd) KPL · breaking out · Most evidence points up · 75% evidence 68.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 32.5/35 · Revenue 47.6% · Profit 95.9% · Operating margin change 4 points · 100% evidence Capital efficiency 17.0/25 · ROCE 24.1% (year to Mar 2026) · Operating margin 27.6% · 100% evidence Valuation 6.5/20 · P/E 45.5× · PEG n/a · 50% evidence Relative strength 12.3/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) 68.2% · 1 year 345.7% · 25% evidence · 9 of 9 weeks ahead Exact sum: 32.5 + 17 + 6.5 + 12.3 = 68.3 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 4. Rubicon Research Ltd this page RUBICON · losing its lead · Most evidence points up · 87% evidence 67.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.0/35 · Revenue 46.3% · Profit 90.1% · Operating margin change 2 points · 100% evidence Capital efficiency 18.8/25 · ROCE 28.4% (year to Mar 2026) · Operating margin 25% · 100% evidence Valuation 8.1/20 · P/E 84.3× · PEG 2.11 · 65% evidence Relative strength 16.5/20 · Strength vs its industry (price vs its 52-week average, weekly) 28.5% · Strength vs NIFTY 500 (same reading) 42.3% · 1 year 144.6% · 70% evidence · 10 of 12 weeks ahead Exact sum: 24 + 18.8 + 8.1 + 16.5 = 67.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 5. [Accent Microcell Ltd](https://www.sectoralpha.in/stocks/accent-microcell-ltd) ACCENTMIC · losing its lead · Most evidence points up · 65% evidence 66.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.8/35 · Revenue n/a · Profit n/a · Operating margin change 7 points · 27% evidence Capital efficiency 21.6/25 · ROCE 24.9% (year to Mar 2026) · Operating margin 23.4% · 100% evidence Valuation 10.1/20 · P/E 25.6× · PEG n/a · 50% evidence Relative strength 12.7/20 · Strength vs its industry (price vs its 52-week average, weekly) 13.6% · Strength vs NIFTY 500 (same reading) 27.2% · 1 year 97.1% · 100% evidence · 11 of 12 weeks ahead Exact sum: 21.8 + 21.6 + 10.1 + 12.7 = 66.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Ajanta Pharma Ltd](https://www.sectoralpha.in/stocks/ajanta-pharma-ltd) AJANTPHARM · quiet · Most evidence points up · 100% evidence 65.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.3/35 · Revenue 25% · Profit 29.8% · Operating margin change 7 points · 100% evidence Capital efficiency 21.1/25 · ROCE 34.5% (year to Mar 2026) · Operating margin 30.6% · 100% evidence Valuation 9.2/20 · P/E 32.4× · PEG 1.91 · 100% evidence Relative strength 5.1/20 · Strength vs its industry (price vs its 52-week average, weekly) -10.2% · Strength vs NIFTY 500 (same reading) 2.4% · 1 year 31.7% · 100% evidence · 8 of 12 weeks ahead Exact sum: 30.3 + 21.1 + 9.2 + 5.1 = 65.7 · What this means: Earnings are strong; relative strength in its sector is -10.2% and the one-year return is 31.7%. 7. [Mankind Pharma Ltd](https://www.sectoralpha.in/stocks/mankind-pharma-ltd) MANKIND · turning · Most evidence points up · 100% evidence 65.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.3/35 · Revenue 13.5% · Profit 27.5% · Operating margin change 2 points · 100% evidence Capital efficiency 15.8/25 · ROCE 13.5% (year to Mar 2026) · Operating margin 27% · 100% evidence Valuation 10.4/20 · P/E 48.3× · PEG 2.64 · 100% evidence Relative strength 12.8/20 · Strength vs its industry (price vs its 52-week average, weekly) -3.4% · Strength vs NIFTY 500 (same reading) 10.8% · 1 year 17.1% · 100% evidence · 4 of 12 weeks ahead Exact sum: 26.3 + 15.8 + 10.4 + 12.8 = 65.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Bliss GVS Pharma Ltd](https://www.sectoralpha.in/stocks/bliss-gvs-pharma-ltd) BLISSGVS · leader · Most evidence points up · 82% evidence 65.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.2/35 · Revenue 25% · Profit 43.1% · Operating margin change 8 points · 95% evidence Capital efficiency 14.5/25 · ROCE 16.9% (year to Mar 2026) · Operating margin 25.9% · 76% evidence Valuation 6.5/20 · P/E 44.8× · PEG n/a · 50% evidence Relative strength 14.1/20 · Strength vs its industry (price vs its 52-week average, weekly) 55.9% · Strength vs NIFTY 500 (same reading) 69.5% · 1 year 325.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 30.2 + 14.5 + 6.5 + 14.1 = 65.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Alembic Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/alembic-pharmaceuticals-ltd) APLLTD · leader · Evidence leans up · 85% evidence 64.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.8/35 · Revenue 19.7% · Profit 32.7% · Operating margin change 5 points · 100% evidence Capital efficiency 12.1/25 · ROCE 12.6% (year to Mar 2026) · Operating margin 21.6% · 100% evidence Valuation 14.5/20 · P/E 24.3× · PEG 1.28 · 100% evidence Relative strength 11.6/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) 24.7% · 1 year 15.9% · 25% evidence · 9 of 12 weeks ahead Exact sum: 25.8 + 12.1 + 14.5 + 11.6 = 64 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Ipca Laboratories Ltd](https://www.sectoralpha.in/stocks/ipca-laboratories-ltd) IPCALAB · leader · Evidence leans up · 82% evidence 62.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.5/35 · Revenue 12% · Profit 73.8% · Operating margin change 2 points · 95% evidence Capital efficiency 15.7/25 · ROCE 17% (year to Mar 2026) · Operating margin 23.1% · 76% evidence Valuation 11.7/20 · P/E 33.5× · PEG n/a · 50% evidence Relative strength 10.5/20 · Strength vs its industry (price vs its 52-week average, weekly) -3.6% · Strength vs NIFTY 500 (same reading) 9.9% · 1 year 28.4% · 100% evidence · 11 of 12 weeks ahead Exact sum: 24.5 + 15.7 + 11.7 + 10.5 = 62.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Fredun Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/fredun-pharmaceuticals-ltd) FREDUN · losing its lead · Evidence leans up · 70% evidence 61.2 out of 100 Growth Capital Valuation Relative 12. [FDC Ltd](https://www.sectoralpha.in/stocks/fdc-ltd) FDC · turning · Evidence leans up · 75% evidence 59.2 out of 100 Growth Capital Valuation Relative 13. [Aurobindo Pharma Ltd](https://www.sectoralpha.in/stocks/aurobindo-pharma-ltd) AUROPHARMA · leader · Evidence leans up · 100% evidence 58.9 out of 100 Growth Capital Valuation Relative 14. [Corona Remedies Ltd](https://www.sectoralpha.in/stocks/corona-remedies-ltd) CORONA · breaking out · Evidence leans up · 73% evidence 58.3 out of 100 Growth Capital Valuation Relative 15. [Lupin Ltd](https://www.sectoralpha.in/stocks/lupin-ltd) LUPIN · quiet · Evidence leans up · 90% evidence 57.2 out of 100 Growth Capital Valuation Relative 16. [Gufic BioSciences Ltd](https://www.sectoralpha.in/stocks/gufic-biosciences-ltd) GUFICBIO · leader · Evidence leans up · 75% evidence 56.8 out of 100 Growth Capital Valuation Relative 17. [ERIS Lifesciences Ltd](https://www.sectoralpha.in/stocks/eris-lifesciences-ltd) ERIS · basing · Evidence leans up · 67% evidence 56.0 out of 100 Growth Capital Valuation Relative 18. [Kilitch Drugs (India) Ltd](https://www.sectoralpha.in/stocks/kilitch-drugs-indialtd) KILITCH · turning · Evidence leans up · 82% evidence 55.8 out of 100 Growth Capital Valuation Relative 19. [Caplin Point Laboratories Ltd](https://www.sectoralpha.in/stocks/caplin-point-laboratories-ltd) CAPLIPOINT · quiet · Evidence leans up · 90% evidence 55.2 out of 100 Growth Capital Valuation Relative 20. [Wockhardt Ltd](https://www.sectoralpha.in/stocks/wockhardt-ltd) WOCKPHARMA · losing its lead · Evidence leans up · 83% evidence 54.7 out of 100 Growth Capital Valuation Relative 21. [Influx Healthtech Ltd](https://www.sectoralpha.in/stocks/influx-healthtech-ltd) INFLUX · quiet · Evidence leans up · 63% evidence 54.3 out of 100 Growth Capital Valuation Relative 22. [Amrutanjan Health Care Ltd](https://www.sectoralpha.in/stocks/amrutanjan-health-care-ltd) AMRUTANJAN · breaking out · Evidence leans up · 90% evidence 54.1 out of 100 Growth Capital Valuation Relative 23. [Akums Drugs & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/akums-drugs-pharmaceuticals-ltd) AKUMS · losing its lead · Evidence leans up · 75% evidence 53.3 out of 100 Growth Capital Valuation Relative 24. [Strides Pharma Science Ltd](https://www.sectoralpha.in/stocks/strides-pharma-science-ltd) STAR · breaking out · Evidence leans up · 82% evidence 52.3 out of 100 Growth Capital Valuation Relative 25. [Zydus Lifesciences Ltd](https://www.sectoralpha.in/stocks/zydus-lifesciences-ltd) ZYDUSLIFE · breaking out · Evidence leans up · 90% evidence 51.5 out of 100 Growth Capital Valuation Relative 26. [Glenmark Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/glenmark-pharmaceuticals-ltd) GLENMARK · breaking out · Evidence leans up · 90% evidence 50.6 out of 100 Growth Capital Valuation Relative 27. [Bafna Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/bafna-pharmaceuticals-ltd) BAFNAPH · breaking out · Evidence leans down · 68% evidence 49.1 out of 100 Growth Capital Valuation Relative 28. [Alkem Laboratories Ltd](https://www.sectoralpha.in/stocks/alkem-laboratories-ltd) ALKEM · quiet · Evidence leans down · 82% evidence 48.3 out of 100 Growth Capital Valuation Relative 29. [J B Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/j-b-chemicals-pharmaceuticals-ltd) JBCHEPHARM · Too little evidence to rank firmly · 59% evidence 45.8 out of 100 Growth Capital Valuation Relative 30. [Bharat Parenterals Ltd](https://www.sectoralpha.in/stocks/bharat-parenterals-ltd) BPLPHARMA · breaking out · Too little evidence to rank firmly · 52% evidence 45.8 out of 100 Growth Capital Valuation Relative 31. [Zim Laboratories Ltd](https://www.sectoralpha.in/stocks/zim-laboratories-ltd) ZIMLAB · leader · Evidence leans down · 74% evidence 42.8 out of 100 Growth Capital Valuation Relative 32. [Bajaj Healthcare Ltd](https://www.sectoralpha.in/stocks/bajaj-healthcare-ltd) BAJAJHCARE · basing · Evidence leans down · 90% evidence 42.7 out of 100 Growth Capital Valuation Relative 33. [Lincoln Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/lincoln-pharmaceuticals-ltd) LINCOLN · quiet · Evidence leans down · 90% evidence 41.5 out of 100 Growth Capital Valuation Relative 34. [Sun Pharmaceutical Industries Ltd](https://www.sectoralpha.in/stocks/sun-pharmaceutical-industries-ltd) SUNPHARMA · quiet · Evidence leans down · 100% evidence 39.8 out of 100 Growth Capital Valuation Relative 35. [RPG Life Sciences Ltd](https://www.sectoralpha.in/stocks/rpg-life-sciences-ltd) RPGLIFE · losing its lead · Evidence leans down · 90% evidence 38.9 out of 100 Growth Capital Valuation Relative 36. [Indoco Remedies Ltd](https://www.sectoralpha.in/stocks/indoco-remedies-ltd) INDOCO · turning · Too little evidence to rank firmly · 52% evidence 37.8 out of 100 Growth Capital Valuation Relative 37. [Suven Life Sciences Ltd](https://www.sectoralpha.in/stocks/suven-life-sciences-ltd) SUVEN · quiet · Most evidence points down · 67% evidence 34.4 out of 100 Growth Capital Valuation Relative 38. [Torrent Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/torrent-pharmaceuticals-ltd) TORNTPHARM · quiet · Most evidence points down · 100% evidence 34.2 out of 100 Growth Capital Valuation Relative 39. [Natco Pharma Ltd](https://www.sectoralpha.in/stocks/natco-pharma-ltd) NATCOPHARM · quiet · Most evidence points down · 90% evidence 31.9 out of 100 Growth Capital Valuation Relative 40. [Dr Reddys Laboratories Ltd](https://www.sectoralpha.in/stocks/dr-reddys-laboratories-ltd) DRREDDY · breaking out · Most evidence points down · 100% evidence 30.4 out of 100 Growth Capital Valuation Relative 41. [Cipla Ltd](https://www.sectoralpha.in/stocks/cipla-ltd) CIPLA · quiet · Most evidence points down · 100% evidence 27.9 out of 100 Growth Capital Valuation Relative 42. [Biocon Ltd](https://www.sectoralpha.in/stocks/biocon-ltd) BIOCON · basing · Most evidence points down · 100% evidence 22.7 out of 100 Growth Capital Valuation Relative 43. [Syncom Healthcare Ltd](https://www.sectoralpha.in/stocks/syncom-healthcare-ltd) SYNCOM · Too little evidence to rank firmly · 17% evidence 42.4 out of 100 Growth Capital Valuation Relative 44. [Sai Parenterals Ltd](https://www.sectoralpha.in/stocks/sai-parenterals-ltd) SAIPARENT · quiet · Too little evidence to rank firmly · 36% evidence 38.3 out of 100 Growth Capital Valuation Relative Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. In this ranking every company's P/E uses its own latest official close and its last four filed quarters, the same rule as the top of this page. ROCE here is each company's last full year, as labelled, so it can differ from the four-quarter ROCE above. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - Formulators](https://www.sectoralpha.in/sectors/pharma-formulators), all 44 compared on one page. ## Which companies are close to Rubicon Research in size? Rubicon Research is the 17th largest of 44 Pharma - Formulators companies on Sector Alpha by market value (at the 18 November 2026 close). Just above it: Ajanta Pharma, J B Chemicals & Pharmaceuticals and Wockhardt. Just below it: Alembic Pharmaceuticals, ERIS Lifesciences and Natco Pharma. ### Pharma - Formulators companies close in size 1. [Ajanta Pharma Ltd](https://www.sectoralpha.in/stocks/ajanta-pharma-ltd) ₹40,910 crore 2. [J B Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/j-b-chemicals-pharmaceuticals-ltd) ₹38,677 crore 3. [Wockhardt Ltd](https://www.sectoralpha.in/stocks/wockhardt-ltd) ₹32,934 crore 4. Rubicon Research Ltd ₹27,451 crore 5. [Alembic Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/alembic-pharmaceuticals-ltd) ₹20,528 crore 6. [ERIS Lifesciences Ltd](https://www.sectoralpha.in/stocks/eris-lifesciences-ltd) ₹18,551 crore 7. [Natco Pharma Ltd](https://www.sectoralpha.in/stocks/natco-pharma-ltd) ₹16,097 crore [All 44 Pharma - Formulators companies, largest first](https://www.sectoralpha.in/sectors/pharma-formulators#all-companies) ### Companies close in size in other industries 1. [Inventurus Knowledge Solutions Ltd](https://www.sectoralpha.in/stocks/inventurus-knowledge-solutions-ltd) ₹27,639 crore · IT Enabled Services/Business Process Outsourcing 2. [Neuland Laboratories Ltd](https://www.sectoralpha.in/stocks/neuland-laboratories-ltd) ₹27,527 crore · Pharma - API & CRAMS 3. Rubicon Research Ltd ₹27,451 crore 4. [Sun TV Network Ltd](https://www.sectoralpha.in/stocks/sun-tv-network-ltd) ₹27,442 crore · Entertainment & Media 5. [Godfrey Phillips India Ltd](https://www.sectoralpha.in/stocks/godfrey-phillips-india-ltd) ₹27,428 crore · Cigarettes & Tobacco Products ## What else do people ask about Rubicon Research? ### What is Rubicon Research's share price today? Rubicon Research Ltd's share price is ₹1,658.30, +144.6% over the past year. The whole company is worth ₹27,454 Cr on the market. In the last 52 weeks it traded between ₹615 to ₹1,861; today it is 84% of the way up from the low, 24.5% above its 200-day average (as of 18 November 2026). ### What were Rubicon Research's latest quarterly results? Rubicon Research Ltd reported revenue of ₹576 Cr and net profit of ₹90.0 Cr for the Sep 2026 quarter. Revenue rose 39.8% and profit rose 66.7% compared with a year earlier. Earnings per share were ₹5.47. The operating margin was 25.0%, 2.2 percentage points higher than a year earlier (as of 18 November 2026). ### What is Rubicon Research's market cap? Rubicon Research Ltd's market capitalisation is ₹27,454 Cr at a share price of ₹1,658.30. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 18 November 2026). ### How is Rubicon Research performing? Rubicon Research Ltd's share price has been rising for 48 weeks. In its latest quarter, revenue rose 39.8% and profit rose 66.7% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 2 weeks running (as of 18 November 2026). ### Will Rubicon Research's share price go up? This page does not forecast Rubicon Research Ltd's share price. What it shows instead: the share price is ₹1,658.30, and it has been rising for 48 weeks. Its P/E of 84.3× is higher than 60% of its own last 1 years (as of 18 November 2026). ### Who owns Rubicon Research? Promoters own 51.3% of Rubicon Research Ltd, foreign institutions 9.0%, domestic institutions 15.7% and the public 24.0% (latest quarter). No group of owners changed its stake by a full point over the last two years (as of 18 November 2026). ### Does Rubicon Research have too much debt? No, Rubicon Research Ltd has little debt: its debt is 0.24× its equity, and its operating profit is 10 times its interest bill. FY26 borrowings were ₹311 Cr against equity of ₹1,289 Cr. So the returns on this page come from the business, not borrowed money (as of 18 November 2026). ### Where is Rubicon Research in its business cycle? Rubicon Research Ltd's FY26 operating margin was 22.8%, against a 7-year range of −12.4% to 30.8%. The latest quarter was 25.0%, near the top of its own range. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 18 November 2026). ### What could break the Rubicon Research story? The main question: the share price moved +144.6% in a year while yearly earnings per share moved +71.4%. The difference came from the market paying a higher multiple. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 18 November 2026). ### Is Rubicon Research a stock worth studying right now? What the numbers show: Rubicon Research Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: whether earnings grow into a price that has already moved. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 18 November 2026). ### Is there a Rubicon Research share price forecast for 2026? What management itself guided: FY27 operating margin at 24% plus. ## Lists - Small & mid cap stocks: https://www.sectoralpha.in/small-cap-stocks-india - Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india This is research, not advice. We’re not SEBI-registered.